<DOC>
	<DOCNO>NCT00742079</DOCNO>
	<brief_summary>This study examine whether pretreatment D-cycloserine cognitive behavioral therapy reduce impairment still present people stable case schizophrenia well determine trait make schizophrenic likely respond D-cycloserine treatment .</brief_summary>
	<brief_title>Using D-cycloserine Enhance Benefits Cognitive Behavioral Therapy Schizophrenia</brief_title>
	<detailed_description>Schizophrenia debilitate chronic condition affect approximately 1 % Americans , experience symptom hallucination , delusion , disorder think movement . These symptom describe positive symptom , experienced addition healthy individual experience . Negative symptom , reduction normal functioning , cognitive deficit , problem think , also plague people schizophrenia . The negative symptom cognitive deficit associate schizophrenia produce otherwise healthy people neurotransmitter inhibit glutamatergic N-methyl-d-aspartate NMDA receptor brain . This inhibition NMDA receptor also cause intensification psychotic symptom otherwise stabilize schizophrenic patient . The drug D-cycloserine partially excite NMDA receptor , use help patient anxiety disorder overcome phobias receive cognitive behavioral therapy . This study examine whether D-cycloserine increase cognitive flexibility someone undergo CBT thereby enhance therapy 's ability reduce patient 's belief paranoid delusion , preoccupation delusion , related distress . All participant screen ensure proper diagnosis schizophrenia without condition . Those pass randomly assign receive either D-cycloserine first placebo pill first . One week screening , participant D-cycloserine group give drug 1-hour session simulate CBT treatment . Those placebo condition receive placebo pill identical session . Two week screen , group call back another session CBT , pill receive switch . Those receive D-cycloserine first week receive placebo , receive placebo receive D-cycloserine . The CBT session attempt increase cognitive flexibility patient ask provide alternate explanation common situation . At screening , start visit first second week , follow-up visit third week , participant undergo series assessment , include interview , computerized test , self-report measure . Belief , preoccupation , distress cause delusion , well degree cognitive flexibility , assess .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>Meets DSMIV criterion schizophrenia , schizoaffective disorder , schizophrenia , paranoid subtype , base chart review , Structured Clinical Interview DSMIV , consultation patient 's clinician Medicated antipsychotic agent clozapine stable dose least 6 week Scores least 3 , `` moderate , '' Scale Assessment Positive Symptoms global delusion rating Paranoid referential delusional content Never engage formal CBT psychotherapy past Diagnosis comorbid Axis I disorder schizophrenia Active substance abuse dependence within 6 month Significant suicidal ideation within 6 week Pregnant nursing Unstable medical disorder impair renal clearance ( creatinine &lt; 60mg/dL/min ) Suffering dementia Suffering seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Paranoid Schizophrenia</keyword>
	<keyword>Paranoid Delusions</keyword>
	<keyword>CBT</keyword>
	<keyword>D-Cycloserine</keyword>
</DOC>